A human clinical trial using a new high specific activity formulation of tin-117m-DTPA has been accepted into the National Cancer Institute Experimental Therapeutics program and Serene will receive significant support, beginning with a Phase 1 trial in patients with bone metastases in 2020. The mission of the NExT Program is to advance clinical practice and bring improved therapies to patients with cancer by supporting the most promising new drug discovery and development projects.